Literature DB >> 2828758

Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.

T Schmeiser1, W Heit, R Arnold, D Bunjes, M Wiesneth, B Hertenstein, W Hampl, H Heimpel.   

Abstract

Conditioning therapy with aggressive chemotherapy and irradiation induces a state of transient combined immunodeficiency in bone-marrow transplant recipients. This promotes the occurrence of severe cytomegalovirus (CMV) infections, the most frequent lethal complication after bone-marrow transplantation (BMT) at present. Forty-four BMT recipients received CMV-IgG-hyperimmunoglobulin for CMV prophylaxis intravenously. The efficacy of this prophylaxis and possible risk factors for the occurrence of CMV-induced interstitial pneumonia (IP) were analyzed. Risk factors for the promotion of a CMV-IP were: additional immunosuppressive therapy after BMT, CMV-positive serostatus of the recipient, CMV-seropositive granulocyte transfusion, CMV infection immediately prior to BMT, and HLA-haploidentical BMT. In this study the incidence of graft-versus-host disease was low and was not associated with the incidence of CMV infections. The use of T-cell-depleted grafts did not result in increased CMV infections or IP and may possibly have improved the immunological reconstitution.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828758     DOI: 10.1007/BF01717831

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  44 in total

1.  Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives.

Authors:  J E Osborn
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

Review 2.  Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients.

Authors:  H Gaya
Journal:  Clin Haematol       Date:  1984-10

Review 3.  Infection in bone marrow transplantation.

Authors:  J D Meyers; K Atkinson
Journal:  Clin Haematol       Date:  1983-10

4.  [Risk factors for the occurrence of pneumonia caused by cytomegaloviruses in patients with bone marrow transplants during prevention with cytomegalovirus hyperimmune globulin].

Authors:  T Schmeiser; W Heit
Journal:  Immun Infekt       Date:  1985-11

5.  Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.

Authors:  W Heit; D Bunjes; M Wiesneth; T Schmeiser; R Arnold; G Hale; H Waldmann; H Heimpel
Journal:  Br J Haematol       Date:  1986-11       Impact factor: 6.998

6.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

7.  Treatment of cytomegalovirus pneumonia with high-dose acyclovir.

Authors:  J C Wade; M Hintz; R McGuffin; S C Springmeyer; J D Connor; J D Meyers
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

8.  IgG-subclass-specific CMV reactivity in bone marrow transplant recipients.

Authors:  B Wahren; A Linde; V A Sundqvist; P Ljungman; B Lönnqvist; O Ringdén
Journal:  Transplantation       Date:  1984-11       Impact factor: 4.939

Review 9.  Herpes virus infections in patients with neoplastic disease. Diagnosis and therapy.

Authors:  K K Wong; M S Hirsch
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

Review 10.  Epidemiology of cytomegaloviral infections: recommendations for prevention and control.

Authors:  I M Onorato; D M Morens; W J Martone; S K Stansfield
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug
View more
  2 in total

Review 1.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow.

Authors:  T Schmeiser; M Wiesneth; D Bunjes; R Arnold; B Hertenstein; W Heit; E Kurrle
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.